Clinical trial delay or failure
Development-stage assets can lose value if enrollment, endpoints, or safety results disappoint.
- Scope
- Cadisegliatin registrational and Phase 2 studies
- Materiality
- high
vTv Therapeutics Inc.
vTv Therapeutics Inc. is a U.S.-based biopharmaceutical company organized as a holding company with operations conducted through vTv Therapeutics LLC. The company focuses on discovering and developing drug candidates, with cadisegliatin as its principal program in diabetes and additional assets licensed from third parties and collaborators.
−100,0 %
13.54
13.54
| % | |
|---|---|
| Clinical-stage drug candidates | 60% Drug programs in human clinical development, including cadisegliatin for diabetes. |
| Licensed preclinical assets | 25% Compounds and programs licensed from partners for discovery and development. |
| Collaboration and milestone revenue | 15% Up-front fees, development milestones, and research fees from partners. |
vTv Therapeutics does not sell commercial drugs today; its economic counterparties are pharmaceutical partners,...
- Pharmaceutical collaboration partnersprimary
Companies or institutions that license programs and pay milestones, up-front fees, or research support.
- Clinical development partnersprimary
Organizations involved in running or supporting trials for cadisegliatin and related programs.
- Future diabetes patientssecondary
Patients who would use an approved therapy such as cadisegliatin if development succeeds.
- Healthcare providers and payorssecondary
Physicians and reimbursement decision-makers who would influence adoption of any approved product.
vTv Therapeutics is headquartered in the United States, but its development model is international because its programs...
- •Headquartered in the United States
- •Clinical development can extend into international trial sites
- •Middle East trial planned with partner G42
- •Future registrational studies expected to be multinational
- •No owned manufacturing footprint; relies on third parties
The company’s strategy centers on advancing cadisegliatin through clinical development and securing the regulatory...
01
Advance cadisegliatin into registrational studiesmedium-term
Clinical proof is the main driver of value for a development-stage biopharma company.
02
Use collaborations to finance developmentshort-term
Milestones, up-front fees, and research payments support operations before product sales exist.
03
Expand international development footprintmedium-term
Broader geography can support enrollment, regulatory strategy, and future market access.
The company faces the core risks of development-stage pharmaceuticals: clinical failure, regulatory delays, safety...
Regulatory approval risk
The company has no approved products and must satisfy FDA and other regulators.
- Scope
- NDA/clinical development pathway
- Materiality
- high
Third-party manufacturing dependence
The company does not own manufacturing facilities and relies on external suppliers.
- Scope
- Clinical supply and future commercial supply
- Materiality
- high
Partner and funding dependence
Milestone and collaboration revenue depends on counterparties and contract continuity.
- Scope
- License agreements and research collaborations
- Materiality
- high
Commercialization and reimbursement risk
Even if approved, uptake depends on pricing, payor coverage, and competition.
- Scope
- Diabetes treatment market
- Materiality
- medium
Revenue recognition for collaboration and milestone payments
Can create large quarter-to-quarter swings in reported revenue
Research and development expense timing
Affects operating loss trends and comparability across periods
Variable-interest entity consolidation
Determines which assets, liabilities, and results appear in the financial statements
Share-based compensation
Can materially affect operating expenses and equity balances
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Viking Therapeutics, Inc.
VKTX · Pharmaceutical Preparations
Viking Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders.
Vistagen Therapeutics, Inc.
VTGN · Pharmaceutical Preparations
Vistagen Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on neuroscience disorders.
MetaVia Inc.
MTVA · Pharmaceutical Preparations
: 29/04/2026